伊立替康联合顺铂同步放化疗治疗晚期宫颈癌的临床价值及毒副反应分析

Clinical Value and Toxic and Side Effects of Irinotecan Combined with Cisplatin by Concurrent Chemoradiotherapy in Treatment of Patients with Advanced Cervical Cancer

目的伊立替康联合顺铂同步放化疗治疗晚期宫颈癌的临床价值及毒副反应分析。方法选取2017年6月—2018年6月我院治疗收治的118例晚期宫颈癌患者为研究对象,按照治疗方案分为观察组和对照组,每组59例。对照组接受顺铂同步放化疗方案,观察组在对照组的治疗基础上联合伊立替康治疗。比较2组治疗效果、生活质量和疼痛程度评定及毒副作用发生率。结果对照组总有效率显著低于观察组(P<0.05),治疗后2组视觉疼痛(VAS)评分较治疗前下降,肿瘤患者生活质量(QOLS)评分显著提高,且观察组优于对照组(P<0.05);对照组血小板减少率高于观察组(P<0.05),2组白细胞减少、中性粒细胞减少、恶心、呕吐、腹泻发生概率比较差异无统计学意义(P>0.05)。结论伊立替康联合顺铂同步放化疗治疗晚期宫颈癌临床效果显著,可有效降低患者疼痛程度,提高患者生活质量水平,毒副反应发生率低。

Objective To analyze clinical value and toxic and side effects of Irinotecan combined with Cisplatin by concurrent chemoradiotherapy in treatment of patients with advanced cervical cancer.Methods A total of 118 patients with advanced cervical cancer admitted during June 2017 and June 2018 were divided into observation group and control group(n=59 in each group)according to different therapeutic Methods.Control group received Cisplatin by concurrent chemoradiotherapy,while observation group was added with Irinotecan on the basis of treatment for control group.Treatment effectiveness,quality of life,assessment of pain degree and incidence rate of toxic and side effects were compared between two groups.Results The total effective rate in control group was significantly lower than that in observation group(P<0.05).After treatment,visual analogue scales(VAS)scores were significantly lower,while QOLS score was significantly improved,and the quality of life scores(QOLS)for tumor patients were significantly higher than those before treatment in two groups;the scores in control group were significantly lower than those in observation group(P<0.05).In control group,decreased rate of platelets was significantly higher than that in observation group(P<0.05),while the differences in incidence rates of leukopenia,neutropenia,nausea,vomiting and diarrhea in control group showed no statistical significances(P>0.05).Conclusion Irinotecan combined with Cisplatin by concurrent chemoradiotherapy in treatment of patients with advanced cervical cancer may achieve good treatment effectiveness,and it may effectively reduce pain degree and improve quality of life with lower incidence rate of toxic and side effects.